ICU Medical (ICU Medical) ROCE % : -1.02% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is ICU Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ICU Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -1.02%.

ICU Medical ROCE % Historical Data

The historical data trend for ICU Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ICU Medical ROCE % Chart

ICU Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

8.29

6.59

7.64

-1.53

0.62

ICU Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-0.17	1.08	0.30	2.08	-1.02

ICU Medical ROCE % Calculation

ICU Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	24.428	/	( ( (4515.641 - 494.559)	+	(4378.439 - 481.838) )	/ 2 )
	=	24.428	/	( (4021.082	+	3896.601)	/ 2 )
	=	24.428	/	3958.8415
	=	0.62 %

ICU Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-39.9	/	( ( (4376.864 - 464.043)	+	(4378.439 - 481.838) )	/ 2 )
	=	-39.9	/	( ( 3912.821	+	3896.601 )	/ 2 )
	=	-39.9	/	3904.711
	=	-1.02 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

ICU Medical (NAS:ICUI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ICU Medical ROCE % Related Terms

Thank you for viewing the detailed overview of ICU Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ICU Medical (ICU Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ICU Medical Inc (NAS:ICUI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

951 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.icumed.com

ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.

Executives

Daniel Woolson	officer: VP, GM-Infusion Capital	ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Christian B. Voigtlander	officer: Chief Operating Officer	951 CALLE AMANECER, SAN CLEMENTE CA 92673
Vivek Jain	director, officer: Chairman and CEO	ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Virginia Ruth Sanzone	officer: VP, General Counsel	951 CALLE AMANECER, SAN CLEMENTE CA 92673
George A Lopez	director, officer: Chairman, other: Chairman	C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
William Seeger	director	951 CALLE AMANECER, SAN CLEMENTE CA 92673
Smiths Group International Holdings Ltd	10 percent owner	C/O SMITHS GROUP PLC, 11-12 ST. JAMES'S SQUARE, 4TH FLOOR, LONDON X0 SW1Y 4LB
Group Plc Smiths	10 percent owner	765 FINCHKEY ROAD, LONDON X0 00000
Kolleen T Kennedy	director	VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Robert S Swinney	director	C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Laurie Hernandez	director	951 CALLE AMANECER, SAN CLEMENTE CA 92673
Brian Michael Bonnell	officer: Chief Financial Officer	ICU MEDICAL INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Scott E Lamb	officer: Controller	ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Kevin J Mcgrody	other: Controller	ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673